Ikena Oncology (IKNA) Stock Analysis

What Ikena Oncology does

Ikena Oncology, Inc. is a biopharmaceutical company specializing in precision oncology. Its primary objective is to create therapeutic agents specifically formulated for patient populations identified through biomarkers, thereby addressing significant unmet medical needs. The company's leading drug candidate is IK-930, an orally administered small molecule designed to inhibit the transcriptional enhanced associate domain (TEAD) transcription factor, a key component of the Hippo signaling pathway. Ikena is also progressing a portfolio of other investigational therapies, including: A small molecule inhibitor program targeting ERK5 within the RAS signaling pathway. IK-175, an oral compound that inhibits the aryl hydrocarbon receptor. IK-007, an orally delivered, selective antagonist of the EP4 receptor, which is being developed for the treatment of microsatellite stable colorectal cancer. Founded in 2016, the company is based in Boston, Massachusetts.

Key metrics

ETFs linked to IKNA

Broad-market and Healthcare sector ETFs an investor holding Ikena Oncology is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how IKNA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Ikena Oncology?

Ikena Oncology trades under the ticker IKNA on NASDAQ.

Which exchange is IKNA listed on?

IKNA is listed on NASDAQ.

What sector does Ikena Oncology operate in?

Ikena Oncology is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze IKNA in a portfolio?

PortView shows IKNA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.